Medical Research News

RSS

New mathematical modeling shows cellular basis of neural transmission

NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for nanodomains and transmitter release," in Nature Neuroscience on Oct. 17, 2010.

3 Nov 2010

Kaiser Permanente awards 792 grants in third quarter 2010

Kaiser Permanente, one of the country's largest not-for-profit health care organizations, funded 792 grants nationwide, totaling approximately $16 million in the third quarter of 2010. Grants awarded to organizations this quarter included funding basic human services in California in a tight economy, offering dental care to women and children in the Mid-Atlantic States, and providing college scholarships to high school students in the Northwest to pursue careers in health care.

3 Nov 2010

LVI in breast tissue predicts recurrence of breast cancer in regional lymph nodes

Breast cancer, one of the most prevalent cancers in women, afflicts an additional 200,000 women each year and causes about 40,000 deaths annually. The disease often extends to neighboring lymph nodes, in part, through lymphovascular invasion (LVI)-a process in which cancer cells invade blood vessels or the lymphatic system-and can often translate into a poor prognosis for patients.

3 Nov 2010

DARA awarded $0.5M grant under Patient Protection and Affordable Care Act for advancing KRN5500 and DB959

DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.

3 Nov 2010

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR International, a Thomson Reuters business.

3 Nov 2010

Curemark awarded QTDP grant to advance development of CM-AT for autism

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.

3 Nov 2010

Synergenz awarded $94,836 research grant under federal QTDP program

Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

Study: Illnesses and injuries that restrict activity linked to worsening functional ability in older adults

A study by Yale School of Medicine researchers reveals that the illnesses and injuries that can restrict the activity of older adults or land them in the hospital are linked to worsening functional ability, especially among those who are physically frail. The report appears in JAMA's November 3 theme issue on aging.

3 Nov 2010

Working at night and in rotating shifts increase risk of work injury

Canadians who work night and rotating shifts are almost twice as likely to be injured on the job than those working regular day shifts, according to a study by researchers at the University of British Columbia.

3 Nov 2010

NIH awards Nemours/Alfred I. duPont Hospital for Children additional $9.5M research grant

The Center for Pediatric Research (CPR) at the Nemours/Alfred I. duPont Hospital for Children was recently awarded an additional 5-year, $9.5-million Center for Biomedical Research Excellence (COBRE) grant from the National Institutes of Health (NIH), National Center for Research Resources (NCRR). This competitive award will allow Nemours to continue to expand the CPR and support the recruitment of additional faculty to this diverse pediatric clinical and research facility.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Drinking beet juice increases blood flow to the brain

Researchers for the first time have shown that drinking beet juice can increase blood flow to the brain in older adults - a finding that could hold great potential for combating the progression of dementia.

3 Nov 2010

Somaxon awarded $245,000 grant for Silenor under QTDP program

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

3 Nov 2010

Researchers reveal molecular structure of blood-clotting enzyme

Using state-of-the-art robotic and x-ray crystallographic equipment, researchers at Saint Louis University have revealed for the first time the molecular structure of the zymogen, or inactive, form of a blood-clotting enzyme.

3 Nov 2010

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

Icagen awarded $733,000 of federal government grants

Icagen, Inc. today announced that it has been awarded approximately $733,000 of federal government grants under the qualifying therapeutic discovery project program under section 48D of the Internal Revenue Code. The program provided for $1.0 billion in federal subsidies in the form of a 50% investment tax credit or an elective 50% cash grant for certain expenses incurred during 2009 or 2010 with an individual taxpayer cap of $5.0 million.

2 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Pain Therapeutics, Inc. announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive funding from these research grants now through the end of 2011.

2 Nov 2010

Palatin receives $978,000 in grants under PPACA

Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.

2 Nov 2010

Medical Research News

New mathematical modeling shows cellular basis of neural transmission

Kaiser Permanente awards 792 grants in third quarter 2010

LVI in breast tissue predicts recurrence of breast cancer in regional lymph nodes

DARA awarded $0.5M grant under Patient Protection and Affordable Care Act for advancing KRN5500 and DB959

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

Curemark awarded QTDP grant to advance development of CM-AT for autism

Synergenz awarded $94,836 research grant under federal QTDP program

Study: Illnesses and injuries that restrict activity linked to worsening functional ability in older adults

Working at night and in rotating shifts increase risk of work injury

NIH awards Nemours/Alfred I. duPont Hospital for Children additional $9.5M research grant

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Drinking beet juice increases blood flow to the brain

Somaxon awarded $245,000 grant for Silenor under QTDP program

Researchers reveal molecular structure of blood-clotting enzyme

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Icagen awarded $733,000 of federal government grants

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Palatin receives $978,000 in grants under PPACA

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News